| Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates |
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. |
zacks.com |
2025-05-08 22:56:06 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights |
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - |
globenewswire.com |
2025-05-08 20:31:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Participate in Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. |
globenewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025 |
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - |
globenewswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 |
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - |
globenewswire.com |
2025-03-15 20:40:00 |
Czytaj oryginał (ang.) |
| Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline |
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline. |
benzinga.com |
2025-03-14 14:09:17 |
Czytaj oryginał (ang.) |
| Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates |
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago. |
zacks.com |
2025-03-13 22:31:04 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights |
– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – |
globenewswire.com |
2025-03-13 18:07:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline |
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – |
globenewswire.com |
2025-03-13 18:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference |
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA. |
globenewswire.com |
2025-03-03 18:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 2:15 p.m. PT / 5:15 p.m. ET in San Francisco, CA. |
globenewswire.com |
2025-01-07 18:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless |
STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows promising efficacy in ovarian cancer, with manageable toxicity, positioning it for potential Accelerated Approval by mid-2027. Financially, STRO has a two-year runway with current cash reserves, but further financing may be needed, risking shareholder dilution. |
seekingalpha.com |
2025-01-02 20:28:24 |
Czytaj oryginał (ang.) |
| Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know |
Sutro Biopharma (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-18 15:00:41 |
Czytaj oryginał (ang.) |
| Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates |
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.81 per share a year ago. |
zacks.com |
2024-11-13 20:41:09 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights |
- Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology - |
globenewswire.com |
2024-11-13 18:30:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference |
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations at the 15th Annual World ADC Conference, taking place in San Diego, November 4-6, 2024. |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML |
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment. |
globenewswire.com |
2024-11-01 10:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum |
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations |
globenewswire.com |
2024-10-10 20:05:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology |
STRO specializes in ADCs for oncology, leveraging XpressCF and XpressCF+ platforms for precise antibody-drug conjugates without living cells. STRO-002, a promising ADC for ovarian cancer, has shown favorable safety and efficacy in trials, with potential FDA approval by 2026-2027. Collaborations with Merck, Vaxcyte, and Astellas Pharma could generate up to $3 billion in milestone payments. |
seekingalpha.com |
2024-09-23 16:46:53 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro's Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee's acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-09-20 20:01:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 |
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) - |
globenewswire.com |
2024-09-14 07:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 |
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET. |
globenewswire.com |
2024-09-11 12:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why |
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer. |
zacks.com |
2024-08-26 15:50:27 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer |
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025. |
globenewswire.com |
2024-08-22 12:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates |
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.64 per share a year ago. |
zacks.com |
2024-08-13 22:45:40 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones |
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - |
globenewswire.com |
2024-08-13 20:30:00 |
Czytaj oryginał (ang.) |
| VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline |
CONROE, Texas , June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as "luvelta", a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers. Sutro, a clinical-stage oncology company pioneering site-specific and novel-format ADCs, has just initiated the randomized portion (Part 2) of REFRαME-O1, a global, registration-directed clinical trial of luvelta (NCT05870748) in platinum-resistant ovarian cancer (PROC). |
prnewswire.com |
2024-06-03 14:00:00 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones |
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - |
globenewswire.com |
2024-05-13 20:30:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for |
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-05-13 15:01:11 |
Czytaj oryginał (ang.) |
| Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial |
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – |
globenewswire.com |
2024-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors |
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors |
seekingalpha.com |
2024-04-05 22:31:56 |
Czytaj oryginał (ang.) |